Dr Laura Kenny is a Consultant in Medical Oncology and she specialises in breast cancer. She trained in medicine at Queen's University Belfast and after following initial registrar training, she moved to London to study for a PhD in translational molecular imaging in the Cyclotron Building, Imperial College London. Her NHS clinical practice is based at Charing Cross and Hammersmith Hospitals (part of Imperial College Healthcare NHS Trust) and she also sees patients privately. In addition, Dr Kenny is a Clinical Senior Lecturer at Imperial College.
Dr Kenny was awarded a Westminster Medical School Oncology Trustee's fellowship and her research has focused on the use of novel PET radiotracers for studying proliferation (fluorothymidine (FLT)), angiogenesis (fluciclatide (AH-111585), and choline metabolism in breast cancer patients. Her work has been published in Cancer Research, Clinical Cancer Research, the Journal of Nuclear Medicine, and the European Journal of Molecular Imaging and Nuclear Medicine.
She was awarded a prestigious NIHR/MRC clinician scientist fellowship in 2010, with the aim of the project being to establish new methods for defining the imaging phenotype in patients, which will help predict drug resistance and drug sensitivity at early timepoints to established and novel cancer therapeutic agents. Her research has been recognised by the American Association of Cancer Research (Young Investigator Award), American Society of Clinical Oncology (Merit Award), British Cancer Research Meeting (Translational Research Award), and she also won the McElwain prize.
Dr Kenny was also appointed as Director of Early Phase Clinical Trials in Cancer, where her aim is to expedite clinical drug development with novel approaches to clinical trials. She was also awarded an MRC DPFS project grant to study a new Affibody probe which will target her2 expression in breast cancer, this will be a first in man study and involves collaboration with four leading oncology centres in the UK.